The COVID-19 pandemic brought an enormous urgency to the life sciences sector. Companies vied for suitable treatments and in less than a year, COVID-19 vaccines were developed. This demonstrated clearly that the sector could move at speed when necessary. Though vaccines were supported by regulators, inefficiencies in vaccine and drug development were exposed.